Most Recent Articles by Laura Stiles
The Janssen Pharmaceutical Companies of Johnson & Johnson have announced the results of 2 long-term phase 3 clinical trials examining esketamine nasal spray in patients with treatment-resistant depression.
Widespread use of antidepressants may be contributing to long-term increased risk for weight gain.
Dr Stewart has held executive leadership positions in public behavioral health systems in Michigan, New York, and Pennsylvania. Her career has spanned 3 decades in public sector administration.
This study had a sample size large enough to assess the effect of circadian disruption on mental health disorders, and was the first to objectively measure patterns of rest and activity (using accelerometers).
Electroconvulsive therapy (ECT) has been used for refractory psychiatric conditions in the United States since 1938. Despite this, few practitioners are comfortable recommending ECT for minors.
More Articles by Laura Stiles
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Transference in the Age of #MeToo: What Counts as Harassment From a Patient?
- Models Derived From Electronic Health Records Effective in Predicting Suicide Risk
- Autonomic Function May Have Directional Effect on Depression
- Predictors of Long-term Medication Adherence in Children With ADHD
- Probiotics Effective in Reducing Rehospitalization for Patients With Mania
- Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy
- ADHD Treatments
- Pharmacogenetics in Psychiatry: Promising Developments and Potential Pitfalls
- Esketamine Nasal Spray: A New Treatment Possibility for Treatment-Resistant Depression
- Substance Abuse and Primary Psychosis: A Closer Look